Biotechnology
Build Your Comparison
Side-by-side financial analysisStock Comparison
ANL vs CAN vs MARA vs ZLAB vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Computer Hardware
Financial - Capital Markets
Biotechnology
Banks - Diversified
ANL vs CAN vs MARA vs ZLAB vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | Computer Hardware | Financial - Capital Markets | Biotechnology | Banks - Diversified |
| Market Cap | $322M | $203M | $5.37B | $1.89B | $896.00B |
| Revenue (TTM) | $6M | $530M | $868M | $453M | $280.33B |
| Net Income (TTM) | $-54M | $-210M | $-2.04B | $-178M | $57.05B |
| Gross Margin | 100.0% | 7.8% | 0.3% | 57.9% | 60.0% |
| Operating Margin | -10.0% | -19.3% | 16.9% | -53.5% | 25.9% |
| Forward P/E | — | — | — | — | 14.4x |
| Total Debt | $27M | $55M | $3.65B | $224M | $942.38B |
| Cash & Equiv. | $61M | $81M | $547M | $680M | $343.34B |
ANL vs CAN vs MARA vs ZLAB vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 23 | Jun 26 | Return |
|---|---|---|---|
| Adlai Nortye Ltd. (ANL) | 100 | 68.8 | -31.2% |
| Canaan Inc. (CAN) | 100 | 17.6 | -82.4% |
| Marathon Digital Ho… (MARA) | 100 | 165.6 | +65.6% |
| Zai Lab Limited (ZLAB) | 100 | 70.2 | -29.8% |
| JPMorgan Chase & Co. (JPM) | 100 | 221.2 | +121.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ANL vs CAN vs MARA vs ZLAB vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ANL is the #2 pick in this set and the best alternative if momentum is your priority.
- +5.5% vs ZLAB's -60.3%
CAN ranks third and is worth considering specifically for growth exposure.
- Rev growth 96.7%, EPS growth 51.1%, 3Y rev CAGR -6.7%
- 96.7% revenue growth vs ANL's -100.0%
MARA is the clearest fit if your priority is value.
- Better valuation composite
ZLAB is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.15, Low D/E 31.3%, current ratio 2.45x
- Beta 1.15, current ratio 2.45x
JPM carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 15 yrs, beta 0.94, yield 1.9%
- 465.8% 10Y total return vs ANL's -31.2%
- NIM 2.2% vs MARA's 0.1%
- 20.4% margin vs ANL's -8.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 96.7% revenue growth vs ANL's -100.0% | |
| Value | Better valuation composite | |
| Quality / Margins | 20.4% margin vs ANL's -8.3% | |
| Stability / Safety | Beta 0.94 vs CAN's 4.24 | |
| Dividends | 1.9% yield; 15-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +5.5% vs ZLAB's -60.3% | |
| Efficiency (ROA) | 1.3% ROA vs ANL's -50.2%, ROIC 4.5% vs -7.3% |
ANL vs CAN vs MARA vs ZLAB vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ANL vs CAN vs MARA vs ZLAB vs JPM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 5 of 6 categories
CAN leads 1 • ANL leads 0 • MARA leads 0 • ZLAB leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 43194.6x ANL's $6M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to ANL's -8.3%. On growth, CAN holds the edge at +121.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $6M | $530M | $868M | $453M | $280.3B |
| EBITDAEarnings before interest/tax | -$64M | -$140M | $953M | -$227M | $81.4B |
| Net IncomeAfter-tax profit | -$54M | -$210M | -$2.0B | -$178M | $57.0B |
| Free Cash FlowCash after capex | -$67M | $0 | -$385M | -$129M | $100.9B |
| Gross MarginGross profit ÷ Revenue | +100.0% | +7.8% | +0.3% | +57.9% | +60.0% |
| Operating MarginEBIT ÷ Revenue | -10.0% | -19.3% | +16.9% | -53.5% | +25.9% |
| Net MarginNet income ÷ Revenue | -8.3% | -39.7% | -2.3% | -39.3% | +20.4% |
| FCF MarginFCF ÷ Revenue | -10.3% | — | -44.4% | -28.5% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +121.1% | — | -6.5% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +78.7% | +59.4% | -113.5% | -11.1% | +16.0% |
Valuation Metrics
CAN leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $322M | $203M | $5.4B | $1.9B | $896.0B |
| Enterprise ValueMkt cap + debt − cash | $289M | $177M | $8.5B | $1.4B | $1.50T |
| Trailing P/EPrice ÷ TTM EPS | -2.11x | -0.71x | -3.82x | -10.67x | 16.00x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | 14.40x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 0.90x |
| EV / EBITDAEnterprise value multiple | — | — | — | — | 18.36x |
| Price / SalesMarket cap ÷ Revenue | — | 0.38x | 5.92x | 4.11x | 3.20x |
| Price / BookPrice ÷ Book value/share | 4.31x | 0.34x | 1.44x | 2.61x | 2.47x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 8.88x |
Profitability & Efficiency
JPM leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-101 for ANL. CAN carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), CAN scores 6/9 vs ANL's 2/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -101.3% | -60.7% | -51.7% | -24.3% | +15.9% |
| ROA (TTM)Return on assets | -50.2% | -34.6% | -28.0% | -15.5% | +1.3% |
| ROICReturn on invested capital | -7.3% | -24.9% | -9.0% | -41.7% | +4.5% |
| ROCEReturn on capital employed | -103.8% | -29.7% | -12.1% | -27.2% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 | 3 | 3 | 5 |
| Debt / EquityFinancial leverage | 1.07x | 0.13x | 1.05x | 0.31x | 2.60x |
| Net DebtTotal debt minus cash | -$34M | -$26M | $3.1B | -$455M | $599.0B |
| Cash & Equiv.Liquid assets | $61M | $81M | $547M | $680M | $343.3B |
| Total DebtShort + long-term debt | $27M | $55M | $3.6B | $224M | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | -28.22x | -104.53x | 12.66x | -30.73x | 0.74x |
Total Returns (Dividends Reinvested)
JPM leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $680 for CAN. Over the past 12 months, ANL leads with a +545.0% total return vs ZLAB's -60.3%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs CAN's -47.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +647.8% | -58.4% | +42.1% | -1.5% | -0.5% |
| 1-Year ReturnPast 12 months | +545.0% | -54.4% | -11.0% | -60.3% | +21.8% |
| 3-Year ReturnCumulative with dividends | -31.2% | -85.7% | +50.9% | -38.2% | +138.2% |
| 5-Year ReturnCumulative with dividends | -31.2% | -93.2% | -53.0% | -90.0% | +118.2% |
| 10-Year ReturnCumulative with dividends | -31.2% | -92.2% | -66.0% | -38.9% | +465.8% |
| CAGR (3Y)Annualised 3-year return | -11.7% | -47.7% | +14.7% | -14.8% | +33.6% |
Risk & Volatility
JPM leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
JPM is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than CAN's 4.24 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 95.1% from its 52-week high vs CAN's 14.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.39x | 4.24x | 3.32x | 1.15x | 0.94x |
| 52-Week HighHighest price in past year | $17.25 | $2.22 | $23.45 | $44.34 | $337.25 |
| 52-Week LowLowest price in past year | $0.88 | $0.31 | $6.66 | $15.96 | $262.71 |
| % of 52W HighCurrent price vs 52-week peak | +59.8% | +14.4% | +60.0% | +38.5% | +95.1% |
| RSI (14)Momentum oscillator 0–100 | 39.0 | 30.1 | 53.5 | 43.4 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 380K | 9.7M | 41.5M | 842K | 7.0M |
Analyst Outlook
JPM leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ANL as "Buy", CAN as "Buy", MARA as "Buy", ZLAB as "Buy", JPM as "Buy". Consensus price targets imply 337.2% upside for CAN (target: $1) vs -11.2% for MARA (target: $13). JPM is the only dividend payer here at 1.86% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $26.00 | $1.40 | $12.50 | $35.00 | $339.75 |
| # AnalystsCovering analysts | 1 | 6 | 20 | 11 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +1.9% |
| Dividend StreakConsecutive years of raises | — | 0 | — | — | 15 |
| Dividend / ShareAnnual DPS | — | — | — | — | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.9% | 0.0% | +3.9% |
JPM leads in 5 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CAN leads in 1 (Valuation Metrics).
ANL vs CAN vs MARA vs ZLAB vs JPM: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ANL or CAN or MARA or ZLAB or JPM a better buy right now?
For growth investors, Canaan Inc.
(CAN) is the stronger pick with 96. 7% revenue growth year-over-year, versus -100. 0% for Adlai Nortye Ltd. (ANL). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Adlai Nortye Ltd. (ANL) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ANL or CAN or MARA or ZLAB or JPM?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +118. 2%, compared to -93. 2% for Canaan Inc. (CAN). Over 10 years, the gap is even starker: JPM returned +465. 8% versus CAN's -92. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ANL or CAN or MARA or ZLAB or JPM?
By beta (market sensitivity over 5 years), JPMorgan Chase & Co.
(JPM) is the lower-risk stock at 0. 94β versus Canaan Inc. 's 4. 24β — meaning CAN is approximately 350% more volatile than JPM relative to the S&P 500. On balance sheet safety, Canaan Inc. (CAN) carries a lower debt/equity ratio of 13% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
04Which is growing faster — ANL or CAN or MARA or ZLAB or JPM?
By revenue growth (latest reported year), Canaan Inc.
(CAN) is pulling ahead at 96. 7% versus -100. 0% for Adlai Nortye Ltd. (ANL). On earnings-per-share growth, the picture is similar: Adlai Nortye Ltd. grew EPS 68. 3% year-over-year, compared to -314. 5% for Marathon Digital Holdings, Inc.. Over a 3-year CAGR, ZLAB leads at 28. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ANL or CAN or MARA or ZLAB or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -833. 1% for Adlai Nortye Ltd. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -996. 4% for ANL. At the gross margin level — before operating expenses — ANL leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ANL or CAN or MARA or ZLAB or JPM more undervalued right now?
Analyst consensus price targets imply the most upside for CAN: 337.
2% to $1. 40.
07Which pays a better dividend — ANL or CAN or MARA or ZLAB or JPM?
In this comparison, JPM (1.
9% yield) pays a dividend. ANL, CAN, MARA, ZLAB do not pay a meaningful dividend and should not be held primarily for income.
08Is ANL or CAN or MARA or ZLAB or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Canaan Inc. (CAN) carries a higher beta of 4. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, CAN: -92. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ANL and CAN and MARA and ZLAB and JPM?
These companies operate in different sectors (ANL (Healthcare) and CAN (Technology) and MARA (Financial Services) and ZLAB (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ANL is a small-cap quality compounder stock; CAN is a small-cap high-growth stock; MARA is a small-cap high-growth stock; ZLAB is a small-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while ANL, CAN, MARA, ZLAB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.